The report was based on survey responses from more than 300 U.S. pharmacies.
The average cost of Lispro for uninsured patients was $97.51 — nearly four times higher than the $25 price cap set by Eli Lilly. In addition, 42 percent of the surveyed pharmacies did not have the lower-priced generic in stock.
Eli Lilly, Sanofi and Novo Nordisk — the nation’s three largest insulin manufacturers — all announced insulin price cuts in March. While most of these price drops take effect in late 2023 and 2024, Eli Lilly rolled out a cap for Lispro this May.
Editor’s note: Becker’s has reached out to Eli Lilly for comment and will update the article as more information becomes available.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.